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Objectives: It is estimated that 30% of psoriasis (PSO) patients also develops pso-
riatic arthritis (PSA). This potential disease evolution brings along new symptoms 
such as swollen and painful joints and mobility problems. Since both diseases are 
potentially degenerative, the aim of this study was to measure which group of 
patients (PSO or PSA) is willing to pay most out of pocket to avoid their health related 
quality of life (HRQoL) to worsen. MethOds: 395 US patients diagnosed with either 
psoriasis (n= 151) or psoriatic arthritis (n= 247) completed a questionnaire as part of 
a broader survey of treatment of PSO/PSA. The questionnaire included the EQ-5D-5L 
instrument and accompanying VAS. Patients were additionally asked to indicate by 
reference to the EQ-5D VAS scale the amount of money per month they would be 
willing to pay for treatments that would prevent a decline in HRQoL by 10 points. 
Price sensitivity curves were created by means of linear regression analysis that 
predict the proportion of patients willing to pay a certain amount of $ out of pocket 
per month. Results: For both PSO (R² = 0,82) and PSA (R² = 0,86) monthly cost out of 
pocket (x-variable) was a good predictor of the proportion of patients that is willing 
to pay a certain amount out of pocket per month (y-variable). Regression models 
look as follows. For PSO: y = 0,77e-0,005x for PSA: y = 0,86e-0,007x. To give a specific 
example 42% of the PSA patients is willing to pay $100 per month out of pocket 
whereas this is 47% among PSO patients. cOnclusiOns: PSO patients are prepared 
to pay more out of pocket on a monthly basis to avoid their HRQoL to worsen than 
PSA patients. Further research is required to understand what drives this difference.
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Objectives: To report the long-term effect of certolizumab pegol (CZP) on work-
place and household productivity up to 96 weeks (wks) in patients with axial 
spondyloarthritis (axSpA), including ankylosing spondylitis (AS, meeting modi-
fied New York criteria) and non-radiographic axSpA (nr-axSpA). MethOds: The 
ongoing RAPID-axSpA trial (NCT01087762), is double-blind and PBO-controlled to 
Wk24, dose-blind to Wk48 and open-label to Wk204. Patients had active axSpA, 
according to ASAS criteria, including AS and nr-axSpA patients. Patients originally 
randomized to CZP (200mg Q2W or 400mg Q4W, following 400mg loading dose [LD] 
at Wks 0, 2, 4) continued on their assigned dose in the OLE; PBO patients enter-
ing dose-blind phase were re-randomized to CZP LD followed by CZP 200mg Q2W 
or CZP 400mg Q4W after Wk24 or, for non-responders, after Wk16. The validated 
arthritis-specific Work Productivity Survey (WPS; administered Q4W) assessed the 
impact of axSpA on workplace and household productivity. WPS responses (LOCF 
imputation) in patients originally randomized to CZP are summarized descriptively 
over 96 wks. Results: 325 patients were randomized, of whom 218 received CZP 
(200mg Q2W or 400mg Q4W) from Wk0. Of patients randomized to CZP at baseline 
(BL), 93% completed Wk24, 88% Wk48 and 80% Wk96. At BL, 72% of CZP patients 
were employed outside of the home. Employed CZP patients reported reductions 
in workplace absenteeism and presenteeism to Wk24, with continued improve-
ments to Wk96 (BL: mean 1.8 days missed/month, mean 5.2 days with reduced 
productivity/month vs Wk96: mean 0.6 days missed/month, mean 1.4 days with 
reduced productivity/month). CZP patients also reported continued improvements 
in household productivity and social participation to Wk96 in both dose regimens, 
and similar improvements were observed in AS and nr-axSpA. cOnclusiOns: 
The initial improvements with CZP in workplace and household productivity and 
increased participation in social/leisure activities were continued to Wk96 in axSpA, 
AS and nr-axSpA patients.
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Objectives: To examine the long-term effect of certolizumab pegol (CZP) on 
workplace and household productivity up to 96 weeks (wks) in patients with active 
psoriatic arthritis (PsA). MethOds: The ongoing RAPID-PsA trial (NCT01087788) 
is double-blind and PBO-controlled to Wk24, dose-blind to Wk48 and open-label 
to Wk216. Patients had active PsA and had failed ≥ 1 DMARD. Patients originally 
randomized to CZP (200mg Q2W or 400mg Q4W, following 400mg loading dose [LD] 
at Wks 0, 2, 4) continued on their assigned dose in the OLE; PBO patients entering 
dose-blind phase were re-randomized to CZP LD followed by CZP 200mg Q2W or 
400mg Q4W after Wk24 or, for non-responders, Wk16. The validated arthritis-spe-
cific Work Productivity Survey (WPS) administered Q4W from baseline (BL), assessed 
the impact of PsA on workplace and household productivity in the randomized set. 
WPS responses (LOCF imputation) in patients originally randomized to CZP groups 
are summarized descriptively over 96 wks. Results: 409 patients were randomized, 
of whom 273 received CZP 200mg Q2W or CZP 400mg Q4W. Of patients randomized 
to CZP, 91% completed Wk24, 87% Wk48 and 80% Wk96. In employed patients in both 
CZP groups (60.8% of all CZP patients at BL), decreases in absenteeism and pres-
enteeism to Wk24 were continued up to Wk96 (BL: mean 2.0 and 1.6 days missed/
month in the CZP 200mg Q2W and 400mg Q4W groups, respectively; mean 5.2 and 
5.1 days with reduced productivity/month vs Wk96: mean 0.3 and 0.4 days missed/
month; mean 0.7 and 1.5 days with reduced productivity/month). Improvements in 
household productivity and social participation reported in both CZP groups over 
24 wks were also maintained to Wk96. cOnclusiOns: The initial improvements 
present study was to measure the functional status and quality of life in RD patients receiving 
the biologic agent golimumab in Greece MethOds: A descriptive study was conducted 
estimating the annual Quality-of-Life (QoL) improvement for 148 patients diagnosed 
with rheumatoid arthritis (RA), psoriatic arthritis (PS) and ankylosing spondylitis 
(AS). QoL was estimated with standardized questionnaires such as EQ-5D and HAQ 
questionnaire. In addition, twenty specific parameters including “general health”, 
“severity of pain”, “productivity level” etcetera wereassessed on 10-point Likert scale. 
Data was collected by doctors across the country at 3 month intervals (4 waves of 
questionnaires during the year). Results: Patients with RA reported improved QoL 
by 14%, followed by 0.67 decrease of average HAQ score. They also reported a 7.5 hours 
gain of working hours and an overall 14% gain in productivity per week. Patients with 
AS were estimated to present 30% improvement in general health condition according 
to their doctors with similar self-reported estimations. Additionally, their QoL was 
improved by 17%. Similarly, patients with PS estimated their QoL improved by 17% 
with a 6hr/week gain in working hours otherwise missed, while the average HAQ score 
fell by 0.71 Findings are in accordance with similar published studies all contributing 
to the general assumption that patients receiving biological agents experience greater 
QoL improvement compared to conservative treatment options. cOnclusiOns: 
Statistical analysis revealed significant improvement of functional status, quality of 
life, productivity gains and decrease of disease activity for those receiving Golimumab 
in Greece for all three disease groups. Amongst limitations, both number of the study 
group and follow-up period should be taken into consideration.
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Objectives: The current prevalence of Chronic Lumbosciatic Syndrome (CLSS) in 
Slovakia ranges in about 170000 cases. The CLSS has a great impact on quality 
of life (QoL) and the ability to work too. Till now in Slovakia was not realised the 
study like this. MethOds: 86 patients with CLSS were studied. The “hospital” and 
the “out-patients clinic” group had 43 vs 43 patients. The average age was 50.36 vs 
51.79 y., weight – 61.04 vs 77.95 kg, duration of illness – 5.3 vs 5.0 years, symptoms 
of illness before diagnosis – 2.27 vs 2.16 years. QoL and the ability to work was 
evaluated on the numeric scale from 0 to 10 (0 for the worst, 10 for the best) by 
patients themselves. Results: The “hospital” and the “out-patients clinic” group 
had these results: the average of hospitalisation – 1.51 vs 1.44 times, incapacity to 
work – 3.06 vs 2.90 months. QoL in the time of good health was 8.2 vs 8.04, in the 
time of diagnosis – 5.86 vs 6.74, and in the current time – 4.58 vs 3.95. The work 
ability (WA) had these results: WA in time of good health was 8.97 vs 9.04 in the 
time of diagnosis – 8.16 vs 8.13, and in the current time – 3.83 vs 3.83. The impact 
of the treatment on the QoL was 5.37 vs 6.06 and on the patients families QoL it 
was 6.16 vs 6.13. The willingness to pay for the perfect cure was 477.90 € vs 524.41 € 
per month (the average salary in Slovakia in 2013 was 824 € ). cOnclusiOns: CLSS 
has a great impact on QoL and on the WA too. There was not statistical difference 
between both “hospital and out-patient clinic” patients in the QoL and WA. Early 
diagnosis is important to effective treatment.
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Objectives: For patients with rheumatoid arthritis (RA) and inadequate response 
to traditional therapy, treatment with biologics is recommended to reduce dis-
ease progression and improve HRQol. Nevertheless, up to 30% of patients stop 
treatment on their own initiative. Aim of the study is to develop and validate an 
instrument to assess reasons for treatment discontinuation of biologics in patients 
with RA. MethOds: We conducted expert interviews with rheumatologists (n= 5) 
to develop a questioning route, which was used in 2 focus groups with a total of 
15 RA patients who dropped out therapy (phase 1). Based on these results a draft 
questionnaire was developed and pre-tested (phase 2; n= 6), resulting in the pilot 
questionnaire. In the validation phase (phase 3) the questionnaire is completed by 
approx. 200 patients, with an interim analysis planned after recruitment of half 
the sample size. Quantitative data analyses will focus on psychometric proper-
ties: missing data, floor/ceiling effects, factorial validity, distribution of properties. 
Patients are recruited at 40 German office based rheumatologists, with 5 patients 
per center. Results: The final questionnaire consists of 82 items covering socio-
demographic aspects, HRQoL, history of treatment and disease, treatment infor-
mation, expectations and satisfaction and ”reasons for discontinuation”. Piloting 
showed that HRQoL, treatment and working-life aspects have impact on treatment 
discontinuation. Particularly, information about treatment options, patient-doctor 
relationship and financial burden were addressed. The questionnaire has proven 
to be feasible in field-test. Validation phase is currently ongoing; results from the 
interim analysis will be presented. cOnclusiOns: Interviews with experts and 
patients demonstrated that treatment discontinuation is triggered by multiple rea-
sons. A targeted developed questionnaire is necessary to identify latent reasons for 
treatment discontinuation. Furthermore, an “easy-to-use” questionnaire could be 
used in daily routine to identify patients likely to withdraw treatment and need 
special patient adherence programs.This research was funded by Pfizer GmbH.
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